Early Intervention with Radicava Beneficial in ALS

Share this content:
The group who received Radicava for the full 48 weeks had ALSFRS-R scores that continued to show significant reductions
The group who received Radicava for the full 48 weeks had ALSFRS-R scores that continued to show significant reductions

Data from the open-label extension trial of Radicava (edaravone; MT Pharma), the first new amyotrophic lateral sclerosis (ALS) treatment in over 20 years, showed that early intervention led to less decline in physical function for ALS patients.

The Food and Drug Administration's (FDA) approval of Radicava was based on 6 month results from the MCI186-19 study, in which 137 ALS patients were randomized 1:1 to either Radicava or placebo. In the open-label extension phase, those who received placebo for the first 6 months began on Radicava, while the initial Radicava arm continued the treatment for another 6 months.

The group who received Radicava for the full 48 weeks had ALSFRS-R scores (a validated rating system for monitoring disability in patients with ALS) that continued to show statistically significant reductions for the rate of decline in physical function versus those who only began Radicava treatment after 6 months on placebo. 

There was also an approximate 58% relative risk reduction in death or certain disease progression events in the 48-week Radicava group versus those given placebo initially.

“The 12-month data […] suggests that early intervention with Radicava may lead to a meaningful clinical benefit when promptly initiated in people with ALS,” said Jean Hubble, MD, VP Medical Affairs, MT Pharma America. “We strongly believe in the potential of Radicava to help people with this devastating disease, and are committed to continuing to advance clinical evidence for this treatment option.”

For more information call 844-772-4548 or visit Radicava.com.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs